Clinical TrialJul 28, 2026, 07:48 AM
Clearmind Completes Part A of Phase I/II Clinical Trial for AUD Treatment
AI Summary
Clearmind Medicine Inc. announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for Alcohol Use Disorder (AUD). All 24 participants across cohorts 1 through 4 have successfully completed treatment according to the study protocol. The company is currently assessing the dataset and, assuming favorable results, intends to initiate the next stage of the clinical program in AUD patients. The multicenter trial is being conducted under FDA oversight at leading sites in the United States and Israel.
Key Highlights
- Clearmind completed treatment for all participants in Part A of its Phase I/II clinical trial.
- All 24 participants across cohorts 1-4 successfully completed treatment for CMND-100.
- The trial evaluates CMND-100 as a treatment for Alcohol Use Disorder (AUD).
- Company is assessing the dataset and plans to initiate the next stage with AUD patients.
- The multicenter trial is conducted under FDA oversight in the US and Israel.
- CMND-100 is a nonhallucinogenic neuroplastogen-derived therapeutic candidate.
Price Impact
More from CMND